A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087).
Stephen R WalshCynthia L GayShelly T KarunaOllivier HyrienTimothy SkallandKenneth H MayerMagdalena E SobieszczykLindsey R BadenPaul A GoepfertCarlos Del RioGuiseppe PantaleoPhilip AndrewCarissa KargZonglin HeHelen LuCarmen A PaezJane A G BaumblattLaura L PolakowskiWairimu ChegeSophie JantoXue HanYunda HuangJulie DumondMargaret E AckermanAdrian B McDermottBritta FlachEstelle Piwowar-ManningKelly E SeatonGeorgia D TomarasDavid C MontefioriLucio GamaJohn R Mascolanull nullPublished in: medRxiv : the preprint server for health sciences (2024)
VRC07-523LS was safe and well-tolerated across a range of doses and routes and is a promising long-acting bnAb for inclusion in HIV-1 prevention regimens.